Clinical Implications of Azole Resistance in Aspergillus fumigatus, the Netherlands, 2007-2009

Jan W. M. van der Linden*, Eveline Snelders, Greetje A. Kampinga, Bart J. A. Rijnders, Eva Mattsson, Yvette J. Debets-Ossenkopp, Ed J. Kuijper, Frank H. Van Tiel, Willem J. G. Melchers, Paul E. Verweij

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

335 Citations (Scopus)

Abstract

The prevalence and spread of azole resistance in clinical Aspergillus fumigatus isolates in the Netherlands are currently unknown. Therefore, we performed a prospective nationwide multicenter surveillance study to determine the effects of resistance on patient management strategies and public health. From June 2007 through January 2009, all clinical Aspergillus spp. isolates were screened for itraconazole resistance. In total, 2,062 isolates from 1,385 patients were screened; the prevalence of itraconazole resistance in A. fumigatus in our patient cohort was 5.3% (range 0.8%-9.5%). Patients with a hematologic or oncologic disease were more likely to harbor an azole-resistant isolate than were other patient groups (p

Original languageEnglish
Pages (from-to)1846-1854
Number of pages9
JournalEmerging Infectious Diseases
Volume17
Issue number10
DOIs
Publication statusPublished - Oct-2011
Externally publishedYes

Keywords

  • NERVOUS-SYSTEM ASPERGILLOSIS
  • IN-VITRO SUSCEPTIBILITY
  • ITRACONAZOLE RESISTANCE
  • INVASIVE ASPERGILLOSIS
  • TRIAZOLE RESISTANCE
  • AMPHOTERICIN-B
  • FUNGAL DISEASE
  • CYP51A GENE
  • VORICONAZOLE
  • MUTATIONS

Cite this